Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Neurology | Musculoskeletal | Family Medicine
Disease Category: Fibromyalgia
Location: United States, IL
A study to investigate the safety and effectiveness of milnacipran in the treatment of children and adolescents, aged 13 to 17, with Fibromyalgia.
If the child qualifies for the study, she/he will begin the first part of the study called the Screening Period which can last from 1 to 4 weeks. During the Screening Period, the doctor will determine if your child qualifies to be in the next part of the study called the Open-Label Period where he/she would receive milnacipran or to start receiving a placebo (inactive substance) for the next 8 weeks. At the end of the Open-Label Period, the study doctor will decide if your child qualifies to be in the next part of the study called the Double-Blind Period. If your child qualifies for the Double Blind Period, your child will be assigned by change to either continue receiving milnacipran or to start receiving placebo (inactive substance) for the next 8 weeks.
Study inclusion / exclusion criteria:
- Children between the ages of 13 and 17 who suffer from fibromyalgia.
Chicago Research Center, Inc
3401 N Central Avenue
Chicago, IL 60634
Research Center Information: Chicago Research Center, Inc
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these